SwedenBIO's prize is awarded to a Life Science company that demonstrated successful achievements beyond the usual and that has contributed to increased interest in the industry. This year Ilya Pharma is selected as finalist together with Bioarctic, Galenica, Gedea Biotech, Hansa Medical, Isconova/Novavax, Scandinavian Biopharma, Verigraft, Wilson Therapeutics and Xintela. The jury consists of SwedenBIO's Board and a representative of the year's price sponsor HealthCap.
– Being selected a finalist in Sweden in this competition is yet another confirmation that we are on the right track and doing something extraordinary, says Evelina Vågesjö, CEO Ilya Pharma.
Evelina Vågesjö will attend the event, SwedenBIO Opinion, and the price ceremony at Malmö City Hall on Wednesday, May 16th, between 15:00 and 20:00. She will also together with other life science entrepreneurs and politicians, Lars Hjälmered (M) and the chairman Jennie Nilsson (S), be on stage discussing how the life science industry can grow stronger and what kind of political initiatives that can promotes this. SwedenBIO, LIF and Swedish Medtech will present their joint proposals how to strengthen the Life Science industry and increase Sweden's competitiveness.
More information; http://swedenbio.se/motesplatser/egna-event/opinion/